Haloperidol Richter

Haloperidol Richter is a prescription medication containing the active ingredient haloperidol, a butyrophenone antipsychotic. It is supplied in an oral dosage form and is marketed in the European Union. Haloperidol works as a dopamine D2 receptor antagonist and is used under medical supervision for certain psychiatric conditions. The product is classified as a prescription‑only drug and follows EU regulatory standards and complies with pharmacovigilance requirements.

Haloperidol Richter is indicated for the management of several psychiatric disorders where dopamine blockade is therapeutic.

- Schizophrenia, including acute exacerbations and maintenance therapy. - Acute psychotic episodes associated with mood disorders or substance use. - Tourette syndrome, particularly for reduction of motor and vocal tics. - Severe agitation or aggression in a hospital setting when rapid control is needed. - Short‑term control of delirium‑related psychosis in medically ill patients. - Adjunctive treatment in resistant cases where other antipsychotics have been ineffective.

Side effects of Haloperidol Richter vary in frequency; some are relatively common while others are less frequent but may require medical attention.

Common: - Drowsiness or sedation. - Extrapyramidal symptoms such as tremor, rigidity, or akathisia. - Dry mouth and increased salivation. - Constipation or gastrointestinal discomfort.

Serious: - Neuroleptic malignant syndrome, a rare but life‑threatening reaction. - Tardive dyskinesia, especially with long‑term use. - Significant cardiac arrhythmias, including QT prolongation.

When prescribing Haloperidol Richter, clinicians should evaluate patient history and monitor for conditions that could increase risk of adverse outcomes.

- Assess for cardiovascular disease, as haloperidol can affect heart rhythm. - Use caution in patients with a history of seizures or epilepsy. - Evaluate liver and kidney function before initiating therapy. - Monitor for signs of depression or suicidal thoughts, particularly in younger adults. - Consider dose adjustments in the elderly due to increased sensitivity. - Review any history of movement disorders, such as Parkinson’s disease. - Avoid abrupt discontinuation to reduce risk of withdrawal or rebound psychosis.

Haloperidol Richter may interact with other medications; some combinations should be avoided while others require careful monitoring.

Avoid: - Other dopamine antagonists or high‑potency antipsychotics, which can increase extrapyramidal risk. - Drugs that prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that raise haloperidol plasma levels.

Use with caution: - CNS depressants like benzodiazepines or opioids, which may enhance sedation. - Anticholinergic agents, which can mask early signs of extrapyramidal symptoms. - Lithium, as combined use may increase neurotoxic effects.